Latest Amgen Stories
THOUSAND OAKS, Calif., March 4, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the second quarter of 2015.
DALLAS, March 3, 2015 /PRNewswire/ -- ReportsnReports.com offers Cancer Cachexia - Pipeline Review, H1 2015 research report that provides an overview of the Cancer Cachexia's
Data Evaluating the Effect of Repatha(TM)(Evolocumab) on LDL-C and Cardiovascular Events to be Featured in Late-Breaking Session THOUSAND OAKS, Calif., March 2, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy THOUSAND OAKS, Calif., March
Company to develop AMG 714 for the treatment of diet non-responsive celiac disease and refractory celiac disease (celiac disease-triggered T-cell lymphoma) LEBANON, N.J.
Study Met Primary Endpoint of Progression-Free Survival THOUSAND OAKS, Calif.
THOUSAND OAKS, Calif., Feb.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Feb.
Third Phase 3 Study Met Non-Inferiority and Superiority Endpoints in the Reduction of Parathyroid Hormone THOUSAND OAKS, Calif., Feb.
THOUSAND OAKS, Calif., Feb. 25, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Cowen and Company 35(th )Annual Health Care Conference at 2:50 p.m.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.